Chronic Pain Clinical Trial
Official title:
The Utility of Genetic Testing in Predicting Drug Response in Chronic Pain
Understanding the impact of genetics could aid rational, precision drug choices. In the current study, investigators will focus on whether genetic analysis of drug processing using the Inagene platform could predict efficacy and side effect profile in patients prescribed medication for pain.
Understanding the impact of genetics could aid rational, precision drug choices. In the current study, investigators will focus on whether genetic analysis of drug processing using the Inagene platform could predict efficacy and side effect profile in patients prescribed medication for pain. In the investigator's clinic commonly employed medications included nortriptyline, duloxetine, topiramate, gabapentin, pregabalin, opioids (morphine derivatives, tramadol, tapentadol, buprenorphine patch), cesamet (a synthetic cannabinoid). To the investigator's knowledge this type of study has not been completed in this environment and/or patient population. Research Objectives: The main goal of this study is to determine whether genetic analysis of drug processing could help predict efficacy and side effect profiles of medications in a cohort of patients suffering from chronic pain. In order to control for various clinical factors, patient reported outcomes will also be collected. As a standard part of any patient intake, pain diagrams, measures of pain, function, mental health status and exercise describe the conditions and relative impact will be included. Investigators will include various standardized and/or adapted versions of other questionnaires which will allow investigators to control for known confounders. The following information will be collected at baseline 1. Demographics - age, gender, rank, working status, medical category 2. Patient Reported Outcomes at baseline (Appendix A) 1. Body Pain Diagram 2. Pain, Enjoyment and General Activity Scale (PEG) 3. Pain Disability Index 4. Hospital Anxiety and Depressions Scale (HADS) 5. Adapted Deployment Risk & Resilience Inventory 2 Section J: Unit Support Exercise Questionnaire 6. Brief Trauma Questionnaire (BTQ) 7. Litigation Status The following information will be collected at follow up, defined by discontinuation of medication or continuation on medication associated with predefined measure of clinical efficacy 1. Medication Efficacy and Side effect Form - for each prescribed medication noted perceived efficacy, severity of side effects and general comments. This will be completed at either the time of medication discontinuation, or when no further changes to dosing is made. 2. Previous medication taken (Appendix B) - investigators will look specifically at commonly prescribed pain medications, including: nortriptyline, duloxetine, topiramate, gabapentin, pregabalin, opioids (ie morphine derivatives, tramadol, tapentadol, buprenorphine patch), Cesamet and plant based cannabis. If necessary, the patient's health record will be accessed to complete this record 3. Current medications 4. Smoking status and total starting/current dose Clinical efficacy will be defined by achieving 5-8 on the Patient Global Impression of Change scale (PGIC). Medication selection will be done in accordance with current standard of care, patient informed consent and clinical experience. Prescription of medication will not be directed by the results of the genetics analytics. Doses will be adjusted if side effects permit and until clinical efficacy is achieved Classification of inferred phenotypes (i.e. ultrarapid, normal, intermediate and poor metabolizer) will be consistent with the recently published guidance for allele function status. As noted, there are four possible scores for each tested medication, ranging from 1-4, which includes; 1) do not use 2) caution 3) use as directed 4) preferred. For the main analysis, the phenotypes will be grouped 1&2 (do not prescribe) and 3&4 (prescribe) and compared against whether patient responded or not to determine sensitivity and specificity of the genetic testing. Sub-analysis will determine for those that did not respond and whether this was a result of side effects or a lack of efficacy. From a functional standpoint for each recommendation the pharmacogenetics testing will classified into green (prescribe), yellow (caution), red (do no prescribe). All yellow outcomes will be reviewed to determine if the clinical information (ie dosing, smoking, and/or current medications), could allow for re-classification to a green or red recommendation for the purpose of the analysis. The distribution of the prediction score will also be separately evaluated for medications actively taken by participants and for medications that had been discontinued. The distribution of prediction scores will be compared using ANOVA. Genetic prediction scores will be separately compared against participants reported efficacy and side effects profile using Spearman's correlation coefficient, and the respective p values will be calculated, and corrected for multiple comparison Patient Care: Participation in the current study will not impact patient care or impact decision making regarding medication. Each patient is simply evaluating the effects of the medications so that we can compare their experiences with the predictive abilities of genetic prediction score. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|